Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: Long-term follow-up of a pilot study from the Wisconsin Oncology Network

Department of Medicine, University of Wisconsin, Madison, WI, USA.
Leukemia & lymphoma (Impact Factor: 2.89). 09/2011; 52(9):1675-80. DOI: 10.3109/10428194.2011.580404
Source: PubMed


Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3-5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) with maintenance rituximab. The complete response rate was 64%, and median progression-free survival (PFS) 37 months. Herein, we update our results, now with a median follow-up of 62 months. The median PFS is unchanged and the median overall survival (OS) is 70 months. The proportion of patients surviving at 5 years is 62%, comparable to studies using intensive strategies in similar patient populations. No late toxicities were noted in our cohort. These long-term results suggest that the modified R-hyperCVAD regimen with maintenance rituximab is an excellent option for older patients with newly diagnosed mantle cell lymphoma.

8 Reads
  • Source
    • "With the aim of increasing disease control and survival, some authors have proposed a postinduction maintenance strategy for patients with MCL. One agent that proved successful in this context is rituximab [34]. Twenty-two untreated MCLs not candidate for autologous stem cell transplantation were treated with a maximum of 6 cycles repeated every 28 days of modified R-hyper-CVAD (rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) followed by rituximab maintenance (weekly doses every 6 months for a total of 4 courses). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mantle cell lymphoma (MCL) comprises 3-10% of NHL, with survival times ranging from 3 and 5 years. Indolent lymphomas represent approximately 30% of all NHLs with patient survival largely dependent on validated prognostic scores. High response rates are typically achieved in these patients with current first-line chemoimmunotherapy. However, most patients will eventually relapse and become chemorefractory with poor outcome. Alternative chemoimmunotherapy regimens are often used as salvage strategy and stem cell transplant remains an option for selected patients. However, novel approaches are urgently needed for patients no longer responding to conventional chemotherapy. Lenalidomide is an immunomodulatory drug with activity in multiple myeloma, myelodisplastic syndrome and chronic lymphoproliferative disorders. In phase II studies of indolent NHL and MCL lenalidomide has shown activity with encouraging response rates, both as a single agent and in combination with other drugs. Some of these responses may be durable. Optimal dose of lenalidomide has not been defined yet. The role of lenalidomide in the therapeutic armamentarium of patients with indolent NHL or MCL will be discussed in the present paper.
    Advances in Hematology 06/2012; 2012(3):523842. DOI:10.1155/2012/523842
  • Source
    Leukemia & lymphoma 06/2011; 52(9):1617-8. DOI:10.3109/10428194.2011.586078 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intensive induction regimen followed by high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) is frequently used to improve outcomes in patients with mantle-cell lymphoma. The comparative impact of conventional vs intensive induction regimen before transplantation is unknown. Forty-eight patients with mantle-cell lymphoma receiving SCT at our institution between January 2000 and December 2010 were included in this study. At the time of initial presentation, 43 (89.5%) had stage IV disease and 18 (37.5%) received more than one chemotherapy regimen before transplantation. Forty patients underwent auto-SCT and 7 had allogeneic SCT (allo-SCT); 1 patient had an allo-SCT for relapsed disease after auto-SCT. At the time of this analysis (median follow-up of 6 years from diagnosis and 4 years from transplantation), 40 patients (88%) were alive with a 5-year disease-free survival of 74.8%. Age, disease stage, number of regimens pre-SCT, pre-SCT disease status, and type of SCT had no impact on long-term outcomes. Importantly, there were no differences among the types of induction regimen on outcomes in this cohort receiving SCT. Based on our data, we believe that future studies should focus on strategies to prevent disease relapse rather than comparing induction regimens before stem cell transplantation.
    Experimental hematology 01/2012; 40(5):359-66. DOI:10.1016/j.exphem.2012.01.012 · 2.48 Impact Factor
Show more


8 Reads
Available from